메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
이수연 (울산대학교병원 약제팀) 윤태원 (울산대학교병원 약제팀) 손기호 (경성대학교 약학대학)
저널정보
한국병원약사회 병원약사회지 병원약사회지 제32권 제1호
발행연도
2015.2
수록면
21 - 32 (12page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Rivaroxaban is useful advantageous because it does not require routine lab monitoring,such as the PT/INR of warfarin. However, dose adjustments are recommended for patients with renalfailure. Also, deep vein thrombosis and pulmonary embolism are required for the initial treatment,and the initial dose is 15 mg twice daily for 3 weeks. Furthermore, the Health Insurance Review &Assessment Service (HIRA) has regulated the clinical use of rivaroxaban for certain indications. Theserestrictions should be reviewed before prescribing rivaroxaban. The aim of this study was to investigate and evaluate the patterns of rivaroxaban usage, and tomonitor its administration according to the recommended dose and the standards of the NationalHealth Insurance in Ulsan University Hospital (UUH). A retrospective analysis was performed by using an electronic medical record database. This study was conducted through a retrospective medical chart review of 145 patients who received rivaroxabanfrom October 1, 2013 to February 28, 2014 at UUH. The evaluation of rivaroxaban use was based on the standards of the American Society of Health-System Pharmacists, which were modified to fit this study. The results are as follows. First, there were 75 (52%) patients who were 65 years of age or older,consisting of 17 male patients and 58 female patients. Second, there were 7 (5%) patients with moderate renal failure, in which two of them showed nonvalvularatrial filbrillation and required a dosage reduction of rivaroxaban. Third, 137 of 145 patients were consistent with indication criteria (95%), and 86 patients did notreceive National Health Insurance coverage. In this case, 40% of the DUE criteria rate was suitablefor administration. Also, 33 patients suffering from an embolism (DVT or PE) were recommended forthe initial treatment, which is 15 mg twice daily for 3 weeks. However, 26 of those patients received apotentially inappropriate initial treatment, while 7 patients received an appropriate initial treatment. Finally, 4 cases reported to have adverse events. One of the reports consisted of skin rash due to anadverse drug reaction to rivaroxaban. The other three adverse events were unlikely due to rivaroxaban. The justification of use based on indications showed a high rate (95%) of its appropriateness, whilethe justification of use in the other three criteria showed a lower than average rate (37%). One case ofa skin rash was possibly related to an adverse reaction to rivaroxaban. Furthermore, the results of this study show that additional research is warranted on other new oralanticoagulants.
#Rivaroxaban #Drug usage evaluation #Retrospective analysis

목차

등록된 정보가 없습니다.

참고문헌 (28)

참고문헌 신청
Joel G. Hardman / 2001 / Goodman & Gilman's The Pharmacological Basis of Therapeutics / The McGraw-Hill Companies :1526~1527 google schola Baglin T. / 2013 / Clinical use of new oral anticoagulant drugs: dabigatran, rivaroxaban / Br J Haematol 163(2):160~167 google schola Lippincott Williams / 2008 / WilkinsMary :Applied Therapeutics: The Clinical Use of Drugs Ninth :15-5~15-11 google schola 오세일 / 2013 / 새로운 항응고제 / 대한의사협회지 56(1):57~61 google schola Warfarin of Korea Pharmaceutical Information Center google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0